EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome

Tanin Shafaati, Amanda A Greenwell, Christina T Saed, Seyed Amirhossein Tabatabaei Dakhili, Jordan S F Chan, Linyue Dong, Magnus J Stenlund, Sally R Ferrari, Ruth Han, Jennifer Kruger, Farah Eaton, Keshav Gopal und 3 weitere

Journal of Pharmacy & Pharmaceutical Sciences · 2025

DOI: 10.3389/jpps.2025.15688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2025. Verfasst von Tanin Shafaati und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Barth Syndrome, Ketones, Cardiomyopathy, Hypertrophic, Transcription Factors. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heart and Stroke Foundation of Canada, Barth Syndrome Foundation, Canada Research Chairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Mutations in the tafazzin gene lead to impaired remodeling of cardiolipin, thereby impairing mitochondrial function and causing Barth syndrome (BTHS), a rare X-linked genetic disorder characterized by cardiomyopathy. Previous studies in a mouse model of BTHS, secondary to knockdown of Tafazzin (TazKD mice), also observed perturbations in mitochondrial substrate metabolism and a hypertrophic cardiomyopathy. BTHS may be characterized by increased cardiac ketone metabolism, as myocardial protein expression of the ketolytic enzyme, β-hydroxybutyrate dehydrogenase 1 (BDH1), was markedly increased in TazKD mice. We therefore determined whether increasing ketone supply in TazKD mice may have therapeutic utility against their cardiac abnormalities.

Methods

We treated TazKD mice and their wild-type littermates with either the sodium-glucose cotransporter-2 inhibitor, empagliflozin (10 mg/kg), or a ketone ester (KE; 1719 mg/kg) once daily for 7-week, and performed ultrasound echocardiography to assess cardiac structure and function.

Results

Treatment of TazKD mice with either empagliflozin or a KE increased circulating ketone levels. However, neither approach proved capable of alleviating the cardiac hypertrophy present in TazKD mice, as their increased left ventricular wall thickness and decreased left ventricular diameter remained comparable to that observed in vehicle control treated animals. We also observed that empagliflozin and KE treatment did not impact key markers of cardiac hypertrophy in TazKD mice.

Conclusion

Increasing circulating ketone levels did not alleviate the cardiac hypertrophy in TazKD mice, suggesting that such an approach would not improve outcomes in BTHS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Barth SyndromeKetonesCardiomyopathy, HypertrophicTranscription FactorsAnimalsMiceDisease Models, AnimalAcyltransferasesSodium-Glucose Transporter 2 InhibitorsMaleMice, KnockoutMice, Inbred C57BLGene Knockdown Techniques

Stichwörter der Autor:innen

Barth syndromecardiomyopathyempagliflozinketonessubstrate metabolism

Substanzen

tafazzin protein, mouseAcyltransferasesKetonesSodium-Glucose Transporter 2 InhibitorsTranscription Factors

Autor:innen und Institutionen

  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
  • Cardiovascular Research Centre, University of Alberta, Edmonton, AB, Canada.
  • Women and Children's Health Research Institute, University of Alberta, Edmonton, AB, Canada.
  • Health Sciences Laboratory Animal Services, University of Alberta, Edmonton, AB, Canada.
  • Department of Obstetrics and Gynaecology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
  • Divsion of Cardiology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.

Förderung

  • Heart and Stroke Foundation of Canada
  • Barth Syndrome Foundation
  • Canada Research Chairs

Zitieren

APA

Shafaati, T., Greenwell, A. A., Saed, C. T., Tabatabaei Dakhili, S. A., Chan, J. S. F., Dong, L., Stenlund, M. J., Ferrari, S. R., Han, R., Kruger, J., Eaton, F., Gopal, K., Davidge, S. T., Oudit, G. Y., & Ussher, J. R. (2025). Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2025.15688

Vancouver

Shafaati T, Greenwell AA, Saed CT, Tabatabaei Dakhili SA, Chan JSF, Dong L, et al. Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome. Journal of Pharmacy & Pharmaceutical Sciences. 2025. doi:10.3389/jpps.2025.15688

BibTeX
@article{Shafaati2025,
  author = {Shafaati, Tanin and Greenwell, Amanda A and Saed, Christina T and Tabatabaei Dakhili, Seyed Amirhossein and Chan, Jordan S F and Dong, Linyue and Stenlund, Magnus J and Ferrari, Sally R and Han, Ruth and Kruger, Jennifer and Eaton, Farah and Gopal, Keshav and Davidge, Sandra T and Oudit, Gavin Y and Ussher, John R},
  title = {Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2025},
  doi = {10.3389/jpps.2025.15688}
}
Kostenlos starten →